46 per cent of patients saw no MS progression five years...

Discuss stem cells, adult and embryonic, and their therapeutic potential for MS here.
Post Reply
User avatar
MSUK
Family Elder
Posts: 2903
Joined: Wed Oct 14, 2009 2:00 pm
Contact:

46 per cent of patients saw no MS progression five years...

Post by MSUK » Wed Mar 01, 2017 6:20 am

46 per cent of patients saw no MS progression five years after receiving AHSCT treatment

New research from Dr Paolo Muraro, of the Department of Medicine at Imperial College London and his colleagues recently reported further evidence of autologous hematopoietic stem cell transplantation (AHSCT) as an effective treatment for multiple sclerosis (MS)...Read more - http://www.ms-uk.org/46-cent-patients-s ... ent-010317
MS-UK - http://www.ms-uk.org/

ElliotB
Family Elder
Posts: 1931
Joined: Mon Feb 03, 2014 4:08 pm

Re: 46 per cent of patients saw no MS progression five years

Post by ElliotB » Wed Mar 01, 2017 7:26 am

Since approximately 70% of those with MS do well regardless of treatment(s)/diet/exercise, I am not sure if this is a good result or not. That is the problem with any kind of treatment(s) - you just never really know if it/they are working or not.

User avatar
Petr75
Family Elder
Posts: 426
Joined: Sat Oct 19, 2013 10:17 am
Location: Czech Republic

Re: 46 per cent of patients saw no MS progression five years...

Post by Petr75 » Sat Sep 28, 2019 11:34 am

2019 Jun 24
Postgraduate Course, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
Autologous Hematopoietic Cell Transplantation in Multiple Sclerosis: Changing Paradigms in the Era of Novel Agents
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6612973/

Abstract

Autologous hematopoietic stem cell transplantation (AHSCT) is established as a standard of care for diseases ranging from hematological malignancies to other neoplastic pathologies and severe immunological deficiencies. In April 1995, our group performed the first AHSCT in progressive multiple sclerosis (MS). Since then, a plethora of studies have been published with encouraging but controversial results. Major challenges in the field include appropriate patient selection, improvements in AHSCT procedure, and timing of this treatment modality. Beyond AHSCT, several new intravenous or oral agents have been developed and approved over the last 20 years in MS. The emergence of multiple effective therapies for MS has created a challenging scenario for both treating physicians and patients. Novel cell-based therapies other than AHSCT are also currently investigated in MS patients with promising results. Our review is aimed at summarizing state-of-the-art knowledge on basic principles and results of AHSCT in MS and its role compared to novel agents.

Post Reply
  • Similar Topics
    Replies
    Views
    Last post